New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
08:19 EDTJNJ, RBGPF, CGJohnson & Johnson sees deal to sell K-Y brand to Reckitt closing mid-year
Sees sees deal to sell K-Y brand to Reckitt Benckiser (RBGPF) closing mid-year. Says offer from Carlyle Group (CG) to acquire Ortho-Clinical Diagnostics expected to close mid-year. Comments from slides that will be presented on the Q1 earnings conference call.
News For JNJ;RBGPF;CG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
16:39 EDTJNJCMS discloses drug makers' payments to doctors, WSJ says
Subscribe for More Information
15:40 EDTJNJJ&J deal for Alios sets valuation benchmark for Novavax, says Piper Jaffray
Subscribe for More Information
12:40 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
12:03 EDTJNJAchillion sinks after Johnson & Johnson buys competitor
The shares of Achillion (ACHN), which has developed a treatment for hepatitis C based on a nucleotide and has been viewed as a potential takeover target by analysts previously, are falling after Johnson & Johnson (JNJ) announced this morning that it had agreed to acquire privately held Alios Biopharma. Alios has developed a number of nucleotide-based hepatitis C treatments, as well as an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus. WHAT'S NEW: Johnson & Johnson said that it had agreed to buy Alios for $1.75B. Alios has developed a number of nucleotides that could be used to treat hepatitis C virus, or HCV. Gilead's (GILD) popular HCV treatment Sovaldi is also a nucleotide and Achillion is developing its own HCV nucleotide treatment. According to The Street's Adam Feuerstein, Achillion's nucleotide is similar in structure to that of Alios. Johnson & Johnson had previously been rumored to be interested in buying Achillion, Feuerstein noted. WHAT'S NOTABLE: Johnson & Johnson said it was "excited" that its acquisition of Alios would enable it to "explore treatment options for a number of viral infections, including RSV, the last of the major pediatric diseases with no available preventive therapy." Novavax (NVAX) is also developing an RSV vaccine and Johnson & Johnson could have considered acquiring it before buying Alios, Feuerstein contended. PRICE ACTION: Near noon, Achillion fell 6% to $10.11, Gilead was down 0.6% to $106.84, Novavax dropped 1% to $4.27, and Johnson & Johnson rose 0.4% to just under $107 per share.
10:30 EDTJNJJ&J could have considered Novavax, Achillion instead of Alios, TheStreet says
Subscribe for More Information
08:31 EDTJNJJohnson & Johnson agrees to acquire Alios BioPharma for $1.75B
Subscribe for More Information
08:16 EDTJNJTetraphase price target raised to $32 from $20 at JMP Securities
Subscribe for More Information
07:30 EDTJNJSachs Associates to hold a conference
14th Annual Biotech in Europe Forum for Global Partnering and Investment to be held in Basel, Switzerland on September 30-October 1.
September 26, 2014
11:35 EDTCGCarlyle Group to acquire majority interest in six power plants in Georgia
Carlyle Group announced it has agreed to acquire 75.05% of the outstanding interests and operational control of Southeast PowerGen, a portfolio of six natural gas-fired power plants in Georgia, from ArcLight Capital Partners and GIC, Singapore's sovereign wealth fund. Equity capital for the transaction, terms of which were not disclosed, will come from Carlyle Power Opportunities Capital Partners L.P. and Carlyle Power Partners II L.P. The acquisition increases the size of Carlyle’s power generation portfolio to more than 4,300 MW. Southeast PowerGen, presently owned by a consortium of ArcLight Capital Partners, GIC and GE Energy Financial Services, consists of two natural gas-fired combined-cycle power generation facilities and four natural gas-fired peaking facilities totaling 2,815 MWs.
September 25, 2014
18:05 EDTCGCarlyle Group to pay $115M in collusion suit settlement, Reuters says
Carlyle Group is settling a lawsuit that alleged it colluded with other buyout shops to depress deal prices for $115M, says Reuters. The settlement will be paid through a combination of Carlyle Partners IV fund capital, insurance, balance sheet capital, and contributions from some employees of the firm, added Reuters, citing sources. Reference Link
September 24, 2014
17:59 EDTJNJOdds of Colgate-Palmolive takeover rise amid slew of megamergers, Bloomberg says
Subscribe for More Information
September 23, 2014
13:39 EDTCGGIC in talks with Carlyle over possible GBP 2B takeover of RAC, Sky News says
The Government Investment Corporation of Signapore, or GIC, is in talks with the Carlyle Group over a potential takeover of its RAC division, a roadside assistance company, SkyNews reports, citing a person close to the situation. The deal would be valued at more than GBP 2B, and the deal could occur within days, Sky News added. CVC Capital Patners has also expressed interest in buying the RAC unit from Carlyle. A takeover of RAC would end its prospects of becoming a publicly traded company. The board of RAC will meet in the coming days to decide whether the division should go through with an IPO or pursue a sale of the business, Sky News added, citing an insider. GIC would consider taking a minority stake in RAC before its IPO if it decides to go public, the insider added. Reference Link
08:07 EDTJNJFDA Pediatric Advisory Committee to hold a meeting
Subscribe for More Information
September 22, 2014
08:54 EDTCGCarlyle aims to divest shares in oil-unloading system, WSJ says
Subscribe for More Information
07:50 EDTJNJDoctors continue to use morcellators despite FDA warning, J&J halt, WSJ says
Subscribe for More Information
07:07 EDTJNJSynageva appoints Robert Bazemore as COO
Synageva announced the appointment of Robert Bazemore as Chief Operating Officer. Bazemore will oversee the planned global commercial launch of the company's lead program, sebelipase alfa for LAL Deficiency, and will have responsibility for the company's global commercial, market access and medical affairs operations. Bazemore last served at Johnson & Johnson (JNJ) in varoius roles including Vice President, Ethicon New Growth Platforms and President of Janssen Biotech, a part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
September 17, 2014
08:36 EDTJNJJanssen-Cilag announces results from post-hoc canagliflozin analysis
Subscribe for More Information
08:12 EDTJNJJanssen-Cilag announces results from Phase 3 Invokana trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use